Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Equity Average: 2019-2025

Historic Equity Average for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to $1.7 billion.

  • Revolution Medicines' Equity Average rose 8.70% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year increase of 8.70%. This contributed to the annual value of $2.0 billion for FY2024, which is 62.91% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Equity Average is $1.7 billion, which was down 12.20% from $2.0 billion recorded in Q2 2025.
  • Revolution Medicines' Equity Average's 5-year high stood at $2.2 billion during Q1 2025, with a 5-year trough of $524.9 million in Q2 2022.
  • Over the past 3 years, Revolution Medicines' median Equity Average value was $1.7 billion (recorded in 2024), while the average stood at $1.5 billion.
  • Its Equity Average has fluctuated over the past 5 years, first spiked by 414.41% in 2021, then fell by 25.42% in 2022.
  • Over the past 5 years, Revolution Medicines' Equity Average (Quarterly) stood at $620.4 million in 2021, then rose by 10.14% to $683.3 million in 2022, then soared by 94.91% to $1.3 billion in 2023, then surged by 43.84% to $1.9 billion in 2024, then rose by 8.70% to $1.7 billion in 2025.
  • Its Equity Average was $1.7 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $2.2 billion in Q1 2025.